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ABSTRACT 
Asthma is one of the most common chronic diseases among teenagers and young 
adults. The prevalence of asthma among young adults in Sweden is approximately 7-
10%. Despite this, only a limited number of studies have focused on asthma, allergy 
and allergic inflammation in this age group. The aims of this thesis are to study the 
consequences of asthma and allergy in teenagers and young adults, incidence and risk-
factors for death due to asthma, and deterioration in asthma prior and following transfer 
from pediatric to adult health care. As allergic inflammation is involved in a majority of 
asthma patients in this age-group we have further investigated a T cell mediated 
inflammatory mechanism with possible implications in monitoring and modulating 
autoimmune and allergic diseases.                                                                                                                              
PAPER I                                                                                                                                     
During the 1994-2003 period 37 deaths due to asthma were identified. The incidence of 
asthma in 1-34 year-olds decreased during the period from 1.54 to 0.53 per million. 
Common risk-factors were under-treatment, poor adherence to prescribed treatment and 
adverse psychosocial situation. An alarming finding was that 11/37 deaths was 
probably caused by food allergy and 8/37 were associated with exposure to pet dander.  
 PAPER II   
In a 5-year  prospective follow-up study to identify risk factors for deterioration of 
asthma following transfer from pediatric to adult health care 150 teenagers with asthma 
were enrolled. Skin prick test at entrance revealed that 89% were sensitized towards at 
least one of tested allergens. A minority performed with impaired lung function without 
deterioration during the five-year follow up, while bronchial hyper responsiveness 
(BHR) was present in 71% of the subjects at entrance and among 59% at follow-up. 
Risk for persistence of BHR after five years was elevated by poor adherence and 
attenuated by regular physical activity. Working capacity decreased significantly during 
the study period without any correlation to risk factors examined.                            
Paper III  
Interactions between the low-density lipoprotein receptor-related protein 1(LRP1) and 
thrombospondin-1 (TSP-1)  is necessarily for T cell motility and that the motogenic 
LRP/TSP-1 mechanism antagonizes adhesion to ICAM-1 and fibronectin as well as 
TCR induced proliferative responses. This cascade mediates regulatory effects of IL-2 
and IL-4. In addition expression of TSP-1, with known ability to protect against 
inflammation, was increased by IL-2.  
Paper IV 
T cell activation induces arrest of T cell motility through down-regulation of LRP1 
synthesis a concomitant up-regulation of TSP-1 synthesis providing a mechanism for 
enhancement of adhesion of T cells to APC´s stimulating proliferative responses. 
Despite this arrest of motility, co-ligation with CD28 maintains a basal motility level by 
enhancing transport of LRP1 to the cell surface.  
Paper V 
Patients with allergy and psoriasis showed impaired T cell motility and decreased TSP-
1 expression compared to healthy controls. IL-2 was shown to up-regulate the impaired 
motility in patient to the same level as in controls indicating a reversible state probably 
excluding a constitutional defect.  
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1 INTRODUCTION AND BACKGROUND 
1.1 ASTHMA  
Asthma, is a multifactorial disease characterized by variable airflow obstruction, 
bronchial hyperresponsiveness  airway  inflammation and not seldom airway 
remodelling1. During recent years it has become evident that the disease called asthma 
includes a number of different wheezing phenotypes e.g. exercise induced asthma 
(EIA), allergic asthma or unspecific hypersensitive asthma. These different phenotypes 
have usually specific inflammatory characteristics. 
 
1.1.1 Prevalence of asthma 
 The prevalence of asthma among teenagers and young adults in Sweden is  
approximately 7-10%,   depending on criteria employed, which is similar to most 
western countries2-6 . As a consequence, asthma is one of the most common chronic 
diseases in this age group. Several studies have reported an increase in the prevalence 
of asthma the 1960s and the 1980s-1990s which appear to have plateaued in recent 
years7.   
 
1.1.2 Asthma in teenagers and young adults 
Despite the fact that this age-range represents an important period in life the number of 
studies focusing on this age group is limited. As a consequence, much knowledge about 
teenagers and young adults with asthma is obtained by extrapolating results from 
studies on children and young adults.  
 
1.1.2.1 Psychological consequences and adherence to treatment 
The period in life when entering adulthood involves important psychological changes 
for the adolescent as at the same time the teenager/young adult strives for emancipation 
and must make decisions of importance for his/her future life. This period also includes 
a desire for independence and autonomy. These circumstances may be in conflict with 
the knowledge that asthma-related morbidity can be largely preventable by effective 
self-management8-11 . Earlier studies have reported unintentional error such as 
“forgetfulness” as a common barrier to asthma management10, 12, 13 . However, others 
suggest that barriers  to adherence could be more of an intentional and active nature 
with reluctance to comply with medical advice, “trying to forget”10 . In addition there is 
a gender aspect in that males with severe asthma deny their chronic disease to a higher 
extent compared to females10 . Patients with poor socioeconomic standard and 
neurocognitive dysfunctions are less likely to have well-controlled asthma10, 14, 15.  
 
1.1.2.2 Transition from child to adult health care 
In Sweden, transfer from paediatric to adult health care usually occurs when the patient 
is about 18 years of age which is a period when several decisions of great importance 
for future life have to be taken.  In addition transfer to adult health care includes usually 
that he young adult has to take responsibility for their disease. Together with 
physiological changes, psychosocial impact during the adolescent period is supposed to 
have consequences on the outcome of chronic diseases as mentioned above. The need 
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of a planned transition to adult health care is exemplified in that despite having the 
lowest rates of hospitalisation, the mortality rate from asthma is 3-times higher for 
youths aged 15-19 years than for children aged 5-9 years16-22 . According to Blum et al 
medical transition is the “purposeful, planned movement of adolescents and young 
adults with chronic physical and medical conditions from child-centered to adult-
oriented health care systems” 17. A special matter of discussion in Sweden is whether 
patients with asthma should be transferred to an asthma clinic or to primary health care 
system.    
 
1.1.2.3 Longitudinal studies 
Over the last three decades, the reported prevalence of atopy and allergic diseases has 
increased dramatically in many countries23 3. Evidence generated from a large number 
of cohort studies demonstrates that wheezing that begins in early life and continues into 
school age generally persists into adulthood4, 6, 24. The natural history of asthma in 
teenagers and young adults is often characterized by periods of remission for a 
sustained period of time. In a study from New Zealand approximately 30% of young 
adults with a history of childhood asthma who are in remission at 18 years of age will 
relapse by 26 years of age which is in agreement with similar studies from other 
countries25, 26 . The likelihood of relapse has been reported to be associated with atopy, 
smoking and previous BHR. In addition, lung function growth patterns established at 
early school-age generally continue  into middle adulthood4, 24, 27. A general finding is a 
10% decrease in FEV1 and a 5% decrease in FEV1/FVC ratio during early to middle 
adulthood in those with persistent or relapsed wheezing4.  The seriousness of  persistent 
severe asthma is exemplified by Limb et al shoving that this subgroup enters adult life 
with a mean FEV1 of 66% of predicted28, 29.  Predictors of persistent moderate to severe 
asthma are early deterioration of lung function, high serum IgE and persistent 
cough/mucus production30.  
 
1.1.3 Asthma mortality 
Asthma mortality increased, according to several studies between the 1960-80`s in 
most industrial countries, Sweden included31-34. This increase was initially most 
pronounced among adolescents and young adults but later on also in younger ages31. In 
addition, a tendency was observed in that asthma death not only occurred among those 
with severe asthma but also in the subgroup classified as mild or moderately severe 
asthmatics. No single factor explained that this increase in asthma mortality was  pin-
pointed as the triggering mechanism but  increased incidence in allergic diseases, 
indoor pollution, patient compliance and insufficient anti-inflammatory treatment was 
suggested as possible causes31, 32. 
 
Studies of mortality due to asthma in children and young adults have revealed 
decreasing rates in most European countries as well as in the United States during the 
two last decades33, 35, 36.  Despite this, asthma mortality is still reported to remain the 
sixth leading cause of death of children between 5 and 14 years in the Unites States. A 
recent prospective study from Denmark showed an increased mortality rate in patients 
above 15 years of age with asthma37 However, studies of long-term mortality in 
children and young adults with asthma are few. 
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1.2 THE IMMUNE SYSTEM 
The main assignment for the immune system is to protect us from invading pathogens 
and tumours. The nonspecific or innate immune system provides a first line of 
defence and is not specific to a particular pathogen or antigen. The innate immune 
system includes monocytes, macrophages, neutrophils, basophils, mast cell 
precursors, the complement system and an array of enzymes.  
The adaptive or specific immune system includes B- and T lymphocytes and is 
characterised by antigen specificity, diversity, immunological memory and self-
nonself recognition. Effective adaptive immune response requires antigen presenting 
cells including macrophages, dendritric cells and B cells able to ingest, process and 
subsequently present antigen to B and T cells. Unfortunately the immune system may 
also react to allergens and autoantigens leading to development of allergic and 
autoimmune diseases38.  
 
1.2.1 B lymphocytes 
B cells are responsible for the humoral immune response. Naive B cells recognize 
antigen by membrane-bound antibody molecules. When encountering a matching 
antigen the B cell becomes activated and differentiate into memory B cells and plasma 
cells. The plasma cells secrete antigen-specific antibodies to the inducing antigen and 
have little or no antibodies bound to their cell membranes39.  
 
1.2.2 T lymphocytes 
T cells are derived from precursors in hematopoietic tissue, especially the bone 
marrow. In contrast to B cells, T cells migrate to the thymus in order to mature and 
undergo differentiation. T cells are divided in two well-defined subgroups: T cytotoxic 
(Tc) cells characterized by the CD8 marker and T helper (Th) cells characterized by the 
CD4 marker. The latter group is further divided in two subpopulations, Th1 and Th2, 
distinguished by the different panels of cytokine they secret. Additional sub-
populations, are Treg and Th17 T cells. Antibody responses to protein antigens require 
recognition of antigen by Th cells and co-operation between the antigen-specific B cell 
and Th cell40, 41. 
 
 During the maturation process in thymus, T cells capable of binding to self-MHC are 
accepted (positive selection) while T cells with high-affinity receptors for self-MHC or 
have receptors for self-antigen presents by self-MHC are eliminated (negative 
selection). As a consequence only T cells that are self-MHC restricted and self tolerant 
will develop into mature T cells while autoreactive T cells will disappear through 
apoptosis42-44.  
 
1.2.2.1  T cell receptor (TCR) and T cell activation  
 T cells express a unique antigen-binding molecule, the T cell receptor (TCR), on their 
surface. TCR specificity is subdivided into two classes either the αβ or the γδ and their 
corresponding T cell subset named αβ and the γδ T cells. T cells with the αβ subset are 
further divided according to their co-receptors CD4+ (Th) or CD8+ (Tc). 
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The cytoplastic (C-domain) of the TCR is short and unlikely to participate in signal-
transduction to intracellular components. Instead the transmembrane part of the TCR 
domain induces T cell activation through the TCR-CD3-complex45, 46. 
 
The αβ T cell receptor recognises only antigens bound to, and presented by antigen 
presenting cells (APC) associated with MHC-molecules. However, in contrast to αβ T 
cells, the γδ T cells do not require either MHC processing or presentation for antigen 
recognition in a manner which seems more consistent with innate immunity. T cells use 
the TCR to scan APC´s for processed cognate antigenic peptides presented by MHC 
molecule (pMHC)45.  Upon recognition of cognate antigens the T cell forms an 
immunological synapse (IS)47, 48 for contact with APC. Except the TCR/pMHC pair, 
major components forming the IS are CD28, CD4, CD8, interleukins and LFA-1.  
To become fully activated, and not anergic (unresponsive), T cells require additional 
co-stimulation from CD28, often referred as the “secondary signal”.  CD28, expressed 
on almost all resting CD4+ T cells and 50-80% of all CD8+ T cells, has two ligands, 
B7-1 (CD80) and B7-2 (CD86)49. Both these ligands are constitutively expressed on 
dendritic cells and induced on activated macrophages and activated B cells. T cell 
activation through the IS induces T cell proliferation and cytokine production. 
 
1.2.2.2 Cytokines 
Cytokines are soluble regulatory molecules mediating communication between cells. 
When cytokines are secreted by, and acts on other leukocytes they are also referred to 
as interleukins. Major producers of cytokines are Th cells, denditric cells and 
macrophages. Cytokines bind to specific receptors on the surface membrane of target 
cells and regulate intensity and duration of e.g. immune responses (Table 1).  
 
Interleukin-2 (IL-2) and interleukin 4 (IL-4) are of special interest in the context of 
autoimmune and allergic diseases50-52. After many years of assuming that IL-2 was 
solely a growth factor for T cells it is now clear that that this interleukin is essential for 
down-regulation of immune response through induction and maintaining of Treg 
cells51, 52. As a result IL-2 is used in the treatment in autoimmune diseases and GVH-
reactions51, 53.  In contrast IL-4 is associated with adverse responses promoting allergy 
and autoimmunity.  
Table 1. Examples of major cytokines produced by T cells  
 
Chemokines, a group of cytokines plays an essential role in regulating  T cell motility 
as well as most others leukocytes54. A subgroup, “inflammatory chemokines” control 
Cytokine Source Functions 
IL-2 TH1 T- and B cell proliferation, cytokine release, differentiation of  CD4 cells 
IFN-γ " Macrophage activation, enhance antigen presenting by dendritic cells 
IL-12 " TH1 differentiation 
IL-3 TH2 Induce eosinophil proliferation and mast cell degranulation 
IL-4 " TH2 differentiation, B cell maturation and switch  to IgE production  
IL-5 " Eosinophil activation 
IL-10 Broad Major suppressive cytokine 
TGF-β Broad Wound repair, Treg maintenance, inhibits activation of T cells and 
macrophages  
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1.2.1 T lymphocyte adhesion and motility  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Major cell adhesion molecules and chemokines involved in lymphocyte 
extravasation.  
 
Lymphocytes and particularly T cells have a unique capacity to reposition themselves 
between the vascular system and lymphoid and non-lymphoid organs57. The process of 
continual lymphocyte recirculation is essential to allow a maximal number of 
antigenically committed T cells to encounter their cognate antigen. T-cells exit blood 
vessels through a multistep process comprising rolling, adhesion, activation and finally 
diapedesis through junctions between endothelial cells as depicted in Figure 1.  
 
Lymphocytes circulating in the blood have a round shape while adhesion, extravasation 
and migration in tissue T cells require a dynamic and flexible morphology. 
Accordingly, the migrating T cell show an elliptoid, “amoeboid” cell shape with a 
pseudopod protrusion at the leading edge and a trailing uropod58. Antigenic challenge 
induces a proliferative response by arresting migration of T cells whereas tolerance 
maintains migration59-61 . 
 
Naive T cells extravasate only trough regions with specialized endothelial cells in 
postcapillary venules “high-endothelial venules” (HEV) localized in most secondary 
lymphoid organs62. Rolling is mediated by L-selectin (CD62L) expressed on the T cell 
binding to GLY-CAM or CD34 on the HEVs62, 63. In the next step chemokines  (CCL 
19 and CCL 21)  on endothelial cells binds to their receptor CCR7 on the T cell 
mediating activation of integrins LFA-1 and α4β156. These two integrins expressed on 
Rolling Adhesion and activation Diapedesis
T cell Endothelial
cell
L‐selectin GlyCAM‐1
CD34
T cell Endothelial
cell
LFA‐1 ICAM
CCR7
CXCR4
CCL19
CCL21
CXCL12 
T cell Endothelial
cell
LFA‐1 ICAM
CCR1
CCR3
CCR5
CCL5
(RANTES)
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naive T cell binds to their ligands VCAM-1 and ICAM-1 on the endothelial cell 
resulting in firm adhesion64.  
 
In contrast to naive T cells, activated T cells may also extravasate through the 
endothelial tissue outside lymphoid organs. This extravasation is not random as it has a 
tendency to occur in localized area or in specified organs. As a result effector T cells 
tend to home to regions of infection and memory cells to the type of tissue in which 
they first encountered antigen. This “homing” process is facilitated  in that the relevant 
subset of T cells lack the expression of CD62L and CCR7 and instead their migration is 
directed by tissue specific integrins and chemokines resulting in  homing to e.g. the 
Payer´s patch, small intestine, skin,  nasal-associated lymphoid tissue through MALT  
and lung (BALT).  Increasing evidence indicate that antigen presentation by the 
endothelial cell contributes to the development and specificity of T cell adhesion and 
extravasation65-67.  
  
 
At sites of localized inflammation cytokines induce an up-regulation of adhesion 
molecules on endothelial cells such as E- selectin, P-selectin, ICAM and VCAM 
together with increased expression of chemokines such as CCL2 and CCL17. These 
molecules interact with LFA-1, L-selectin and chemokine receptors (e.g. CCR2 and 
CXCR4) resulting in adhesion and extravasation. The complexity of these mechanisms 
is shown in a murine model demonstrating that T cells are activated in the lung before 
entering their target tissue and inducing autoimmune disease68-71.  
 
 
1.2.2 Regulation of the T cell immune response and tolerance 
A first line of protection from autoimmune diseases is mediated through central 
tolerance, the process when autoreactive B cells are eliminated in the bonemarrow and 
autoreactive T cells in thymus. However, some autoreactive B and T cells escape this 
central deletion and appear in the periphery. To prevent these autoreactive cells from 
causing autoimmune diseases they are normally inactivated by peripheral tolerance 
mechanisms and peripheral T cell tolerance to environmental antigens is crucial for 
avoidance of allergy72, 73. 
 
Important components involved in regulation of T cell responses and induction of 
peripheral tolerance are mechanisms regulating T cell migration and the ability to 
stably conjugate with APC. As mentioned above, antigen challenge in vivo inhibit the 
motile behavior of T cells from a random walk to arrested migration, contact with and 
swarming in the proximity of APC cells inducing a proliferative response 59-61 Two co-
stimulatory molecules of the CD28 family, CTLA-4 and PD-1 promote peripheral 
tolerance by attenuating or terminating an ongoing T-cell response74, 75.  
 
 
CTLA-4, only expressed on activated T cells, restricts autocrine IL-2 production and 
inhibits cell cycle progression. At least to some extent CTLA-4 acts by blocking the 
CD28 ligands  (B7-1 and B7-2) and thus preventing the effects of CD28 implicating an 
additional pathway of “fine tuning” T cell activation76. The negative regulatory 
molecule PD-1 is, despite its name, “programmed cell death” associated with 
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downmodulation rather than apoptosis.  PD-1 is, compared to CTLA-4, more 
implicated in peripheral tolerance and accordingly protects from the induction and 
maintenance of autoimmune processes in the periphery74. Although involved in 
peripheral tolerance, CTLA-4 is the primary negative stimulatory molecule within the 
secondary lymphoid tissue75, 77. 
  
Both CTLA-4 and PD-1 overrides the TCR-induced arrest of migration which implies 
that the T cells continue to move as if they never encountered antigen74. Inhibiting the 
“arrested migration” may thus result in immunological tolerance and protection against 
autoimmune diseases. Accordingly, mutations in the CTLA-4 gene have associated 
with several autoimmune disorders such as autoimmune hypothyreoidism and type 1 
diabetes and administration of CTLA-4 is reported to induce transplantation tolerance75, 
77-80. PD-1-defient mice are shown to develop autoimmune diseases such as type 1 
diabetes and arthritis75. Although signals generated by TCR and co-stimulatory 
molecules are required for optimal T cell activation and induction of tolerance it is still 
largely unknown how these signals are integrated by the cell.  
 
 
                                                                                                                                         
1.2.2.1 T-reg cells 
 
 Prevention of autoimmune diseases by establishing self-tolerance 
 Suppression of allergy and asthma 
 Induction of tolerance against dietary antigens 
 Induction of maternal tolerance to the fetus  
 Suppression of pathogen-induced immunopathological reactions 
 Regulation of the effector class of the immune response 
 Suppression of T cell activation triggered by weak stimuli 
 Feedback control of the magnitude of the immune response by effector Th cells 
 Protection of commensal bacteria from elimination by the immune system 
 
Table 2. Functions proposed for Treg cells (modified after A Corthay81) 
 
A T cell population that could suppress immune responses was described in the early 
1970s. This subset, shown to be CD4+ T cells co-expressing CD25, is called T 
regulatory (Treg) cells and defined as T cells in charge of suppressing potentially 
deleterious activities of Th cells. Impaired Treg cell development and function is 
associated with autoimmune disorders and allergy82, 83 (Table 2). However, the 
classifications and exactly characteristics of Treg cell remains controversial81.  In 
addition to CD25, a generally accepted marker of Treg cells is Foxp3, a transcription 
factor which is believed to control many of its function84. This definition of T-reg cells 
has been questioned as both CD25, Foxp3 and several others markers of Treg are 
expressed on activated Th cells85, 86. Consequently, a generally accepted Treg-specific 
marker is still lacking. Additionally, the ability to suppress T cells is not an exclusive 
property of Treg cells as all CD4+ T cells appear to exert various kinds of suppressive 
activities. For instance, Th1 cells secrete IFN-γ slowing down the proliferation of Th2 
cells. In contrast, the secretion of IL4 and IL-10 by Th2 cells hamper Th1 development.   
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Suppression mediated by Treg cells is antigen specific.  Since the discovery, Treg cells 
have been suggested to be involved in several immunomodulating reactions of which 
some are listed in table 2. Transforming growth factor β (TGF-β) protects against 
autoimmunity.  TGF-β and IL-10 has been suggested to be a mediator of Treg mediated 
suppression. Several different mechanisms have been proposed to explain how Treg 
cells discriminate between cells to suppress and cells not to react with. So far no single 
model explaining this diversity has been generally accepted87.  
 
Whilst several studies identify the capacity of Treg cells to control allergic airway 
inflammation there is no general agreement on the mechanisms involved88-91. In 
experiments with sensitized mice systemic administration of purified antigen-specific 
CD4+CD25+ Treg cells before challenge inhibited BHR, eosinophil recruitment while 
effect on Th2 cytikines are controversial. In contrast, depletion of CD25+ cells before 
allergen challenge resulted in significantly increased Th2 cytokine response, IgE levels, 
eosinophilia and BHR51, 92-96. Kearely and co-workers have been able to show that 
therapeutic transfer of CD4+CD25+ Treg cells not only resolve established allergen-
induced pulmonary inflammation but also prevent the development of airway 
remodelling.97 In vivo studies are hampered as CD4+CD25+ Treg cells mostly are 
obtained from peripheral blood which is obviously distal from the active site of 
disease98, 99. Additionally there are convincing evidence for a role of Foxp3+ in 
preventing the development of the X-linked autoimmunity-allergic dysregulation 
syndrome (IPEX-syndrom) affecting young boys95.Thrombospondin-1 (TSP-1), a 
protein rapidly expressed in inflamed and damaged tissue induces Treg cells through 
ligation of its receptor CD47100, 101. IL-2 provides protection against autoimmune 
diseases through stimulation of development of Treg cells102. 
In conclusion, although Treg cells are not well characterized they represent an subset in 
the prevention of allergic and autoimmune diseases.  
 
 
 
1.3 THROMBOSPONDIN-1 (TSP-1) AND LOW-DENSITY LIPOPROTEIN 
RECEPTOR-RELATED PROTEIN 1 (LRP1)  
Thrombospondin-1 (TSP-1) belongs to a family of matricellular glycoproteins and is 
a trimer with a MV of 450 kDa and, on reducing gels, 175 kDa for each monomer. 
Each monomer consists of specific domains of which the NH2-terminal heparin binding 
domain and the COOH-terminal cell-binding domain are of special importance103-106. 
The first recognized source of TSP-1 was human platelets but the molecule is today 
known to be expressed on a variety of cells, especially in tissues undergoing 
regeneration such as in rheumatoid lesions107, 108. Furthermore, the role of TSP-1 in 
inflammatory conditions is further demonstrated in animals with defective TSP-1 
expression101, 109-112.  In a model studying allergic asthma in sheep, Huang and co-
workers reported already 1996 increased plasma levels of TSP after allergen 
exposure113, 114. They speculated in a correlation with inflammatory mediated platelet 
activation. However has since then, TSP-1 also been shown to be released from 
activated mastcells.   
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TSP-1 is furthermore an inhibitor of angiogenesis115 and as such indirectly of tumor 
progression through binding to CD36 on endothelial cells in addition to regulate 
spreading and migration for many tumor cells.  
TSP-1 interacts with T cells by binding to CD47, LRP and calreticulin and TSP-1 
promotes generation of Treg cells through CD47 TSP-1 is also an activator of TGF-β 
and may thus regulate immune response through TGF-β100, 101, 116, 117. 
Low-density lipoprotein receptor-related protein 1 (LRP1/CD91), expressed by 
most cell types, is a large cell-surface glycoprotein consisting of two fragments ~515 
kDa and ~85 kDa respectively. As a multifunctional endocytosis receptor it mediates 
internalization and degradation of a large number of ligands and interacts with 
proteases, growth factors and matrix proteins118-121. 
 
 
1.4 ALLERGY 
Among children and young adults with asthma a majority are sensitized to air-borne 
allergens. The term “allergen” refers to nonparasitic antigens which are capable of 
stimulating type I hypersensitive response in allergic individuals on repeated exposure. 
Allergic reactions are divided into four types. Type I-III are mediated by antibody or 
antigen-antibody complexes: IgE-mediated (type I), IgG- or IgM-mediated (type II), 
and immune-complex-mediated (type III). In contrast to type I-III the fourth type, 
termed delayed-type hypersensitivity reaction, is primarily T-cell mediating late 
reactions such as contact dermatitis against nickel or tuberculin (PPD) test.  
 
Common features of IgE mediated allergies are associations with symptoms from the 
airways like asthma and rhinitis. When exposed to a relevant antigen (allergen) Th2 
cells induce plasma cells to secrete IgE-antibodies. This class of anti-bodies binds to 
the high affinity receptor (FcεRI) on the surface of mast cells (in tissue) and basophils 
(in the blood) causing these cells to become “sensitised”. A later exposure to the same 
allergen cross-links with the membrane-bound IgE on these cells causing degranulation 
of different pharmacological active mediators. These mediators can be divided in either 
primary mediators e.g. histamine or secondary mediators such as leukotrienes. The type 
I reaction tends to start immediate after exposure to an allergen and is usually limited to 
one or two organs, often involving epithelial surfaces at the site of allergen entry. 
However, the immediate allergic reaction is often followed by a late phase reaction 
involving cytokines, neutrofiles, eosinofils and T cells. 
In spite of the fact that much is known about factors involved in the process of 
sensitization and the allergic reaction there are still several question-marks.  Examples 
of such issues are the mechanisms responsible for different phenotype expressions of 
allergic diseases such as asthma and how the different factors regulating the allergic 
reaction interact. The role of T cells that are considered to “orchestrate” the allergic 
inflammation is another example of such obscurity122.  
  
 
1.4.1.1 T cell involvement in the allergic inflammation 
One of the first steps in the establishment of allergic sensitization is the generation of 
an antigen-specific T cell with the ability to initiate response to an allergen. The main 
allergen presenting cell in the airways are the dendritic cells (DC) localized beneath the 
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respiratory epithelium. Uptake of allergens by DC is an active process which is thought 
to be facilitated by signals from the epithelium.123, 124 It is speculated that these 
stimulatory signals are increased if the epithelium is damaged by microbes or other 
irritants.  There are several reports indicating the involvement of Toll-like receptors 
(TLR), on epithelial as well as dendritic cells being involved in development of 
allergy125, 126. In the initial sensitization process the DC, when properly stimulated, will 
migrate to the draining lymph node where they interact with naive T cells via TCR, 
MHC class II and co-stimulatory molecules. Examples of co-stimulatory molecules 
involved in these reactions are, as described above, B7 on antigen presenting cells and 
CD28 on T cells.   The interaction with DC is an important step in the process when 
naive T cells differentiate into Th1 and Th2 cells127. 
 Th2 cells and their cytokines are considered to orchestrate the allergic inflammation, 
especially in the airways128, 129. The Th2 cytokines IL-5 and IL-13 is critical for 
allergen-induced eosinophil maturation, recruitment and survival. After the initial 
sensitization to an allergen IL-4 is required for the differentiation of naive T cells into 
Th2 cells. However, the mechanisms responsible for Th2 differentiation during the 
initial sensitization remain unclear. Additionally, both IL-4 and IL-13 are essential in 
the isotype switching of B cells to IgE synthesis. Th1 cells are also recruited into the 
lung during an allergic asthmatic reaction but their roles in the asthmatic response are 
still under debate. There are conflicting reports suggesting that Th1 cells mediate 
regulatory effects as well as enhanceing the allergic reaction.130-132 
 
Signalling through IL-2R and CD28 increase IL-9 secretion by allergen-specific T cells 
which could explain why IL-9 expression increases markedly in response to allergen 
challenge. IL-9 has been implicated in both inflammatory and remodelling process in 
asthma and human trials with monoclonal antibodies against IL-9 has showed some 
evidence of efficacy133. 
 
Chemokine receptors expressed on Th2 cells, such as CCR4 and CCR8 are suggested 
to be responsible for the migration of these cells into the airways, however, several 
questions in this issue remains unanswered134, 135.  
In humans, large reservoirs of tissue-resident memory T cells (TRM) have been 
reported in the skin and the lungs, however it is unclear how TRM cells modulate 
allergic inflammation136. Islam et al have shown that T cell trafficking, necessary for 
asthmatic inflammation, involve both innate and adaptive pathways. A therapeutic 
approach by blocking the tissue- and inflammation-specific trafficking by T cells is the 
use of an antibody to CD11a (Efalizumab)136. It inhibits skin-homing of T cells and has 
been reported to be effective in some individuals with atopic-dermatitis. 
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2 AIMS 
This thesis has two main themes. One aim was to evaluate risk factor for serious 
outcome of asthma in teenagers and young adults. A second aim was to characterize a 
mechanism regulating activation and motility of the T cell and the possible implication 
in allergic and autoimmune inflammation. The specific aims of this thesis were as 
follows: 
  
Paper I. 
To, during a 10-year period, evaluate mortality rate associated with asthma and identify 
risk factors for deaths in asthma in teenagers and young adults 
 
Paper II.  
To evaluate outcome of asthma, impact of atopy and other risk factors for deterioration 
in asthma during and after transfer from paediatric to adult healthcare 
 
Paper III  
To examine the influence of LRP1 and TSP-1 on T cell motility, adhesion and 
proliferation and the influence of IL-2 and IL-4 on TSP-1 expression and motility 
  
 Paper IV 
To examine the influence of T cell activation by antigen on the expression of TSP-1 
and LRP1 with special reference to the arrest of motility induced by activation 
 
Paper V.   
To examine T cell motility and TSP-1 expression in young adults with asthma and 
allergy   
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3 METHODS 
3.1 PAPER I – ASTHMA MORTALITY 
3.1.1 Study design 
A national Swedish Task Force was established to monitor prospectively all deaths of 
children and young adults from asthma during the 10-year period 1994-2003. The 
expert panel included specialists in paediatric and adult asthma, respiratory medicine 
and forensic medicine as well as an asthma-specialist nurse.  
 
3.1.2 Collecting information of deaths 
All death certificates for 1-34 years old which in any part of the certificate contained a 
diagnose related to allergic or respiratory disease were received from Statistics Sweden 
and, later on, from the Centre for epidemiology (EPC) at The National Board of Health 
and Welfare. In order to identify false negative asthma deaths all death certificates with 
a related respiratory tract disease recorded as the underlying cause of death were 
collected. The specific ICD diagnostic codes used were 490-496 and 995 (ICD-9) or 
the ICD-10 codes J40-47 and T28. The age group 1-35 years was selected in order to 
avoid other pulmonary diseases such as chronic bronchitis. Children less than one year 
were not included because of difficulty in diagnosing asthma in this age group. 
Additionally, the medical profession were on several occasions asked to report all 
suspected deaths from asthma in the actual age group.  
Police reports, medical records and autopsy reports for all individuals suspected to have 
died from asthma were collected. Whenever possible the asthma-specialized nurse 
conducted telephone interviews with the next-of-kin employing a modified 
standardized questionnaire developed by the British Thoracic Society and previously 
used in investigations similar to ours137.   
 
3.1.3 Analyzing of data 
Information obtained concerning each suspected death from asthma was carefully 
reviewed by one of the member of the Task force according to a standardized protocol 
and subsequently presented to the rest of the panel. The Task Force met regularly to 
discuss about the patients and  complete a final panel work-sheet in order to determine 
whether the patient had indeed died of asthma and, when possible, identify 
predisposing factors and classify the severity of asthma before death. 
In addition to asthma severity specific risk-factors analyzed were; presence of allergy, 
under-treatment and presence of an adverse psychosocial situation. 
For analysis, the subjects were divided into the following age groups: 1-19 years old 
(n=12, 6 males), 20-29 years old (n=12, 8 males) and 30-34 years old (n=13, 7 males). 
 
3.2 PAPER II – ADOLESCENTS WITH ASTHMA 
3.2.1 Study design 
Adolescents with asthma were recruited at the time when they were transferred from 
paediatric to adult healthcare. Those with mild or moderate asthma assigned randomly 
to primary care or a specialized transition asthma clinic.  Lung function, working 
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capacity, presence of allergy and bronchial hyperresponsiveness were evaluated when 
entering the study and two and five years later.  
 
3.2.2 Study population 
156 adolescents were recruited consecutively when they, due to their age, had their 
final visit at the Children´s Hospital at Huddinge University Hospital, Stockholm.  All 
subjects fulfilled the ATS criteria for asthma and had visited the clinic for regular 
follow-up visits for at least three years. A majority of the teenagers had other allergies 
such as rhinoconjunctivitis, eczema and food allergies. Of the 156 patients originally 
recruited a total of six subjects were excluded due to mental retardation (n=2), chest-
wall disease (n=1) and three declined to participate.   
 
3.2.3 Definition of asthma severity and randomization 
Mild/moderate severe asthma was defined as FEV1 >80% of predicted (% pred) 
managed with a total daily dose <600 µg inhaled corticosteroids (budosemid or 
equivalent). Those who fulfilled these criteria and had no severe food allergy were 
randomly assigned to the transition asthma clinic (n=51) or to primary care (n=46). The 
subjects who were classified as severe were all transferred to the transition asthma 
clinic.  
 
3.2.4 Definition of “poor adherence”  
Subjects who admitted that they on a regular basis did not take their prescribed drugs 
and/or missed more than two consecutive clinical visits without a reasonable 
explanation were classified as “poor adherence”. 
 
3.2.5 Test for allergy 
Skin-prick test was performed in duplicate on the  volar side of the lower arms with 
standard dilutions (100,000 BMU/ml ) of 12 different allergens e.g., birch, timothy 
grass, mugwort, cat, horse, dog, house dust mite (Dermatophagoides pternyssinus), 
mold (Cladosporium, Aspergillus fumigatus and Alternaria), fish and peanut -  utilizing 
Soluprick© allergens (ALK, Abello, Denmark). Histamine  (10 mg/ml) was used as a 
positive and 50% glycerol as a negative control. Wheal diameters of >3 mm after 15 
minutes were considered to indicate a positive reaction. 
 
3.2.6 Lung function 
Forced expiratory manoeuvres were performed according to the criteria of the 
American Thoracic Society (ATS)138 in the standing position without noseclips 
employing a Vitalograph spirometer (Vitalograph Ltd , Buckingham, UK). All tests 
were conducted by one of the co-authors (K S-B) , using the same spirometer which 
was calibrated daily.  The highest value of three valid measurements of FEV1 was 
recorded. Spirometric values are expressed as percentages of the reference values (% 
pred) provided by Zapletal139 for individuals younger than 18 years of age and the 
ECCS for those older140. 
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3.2.7 Bronchial challenge 
Presence of bronchial hyperreactivity responsiveness (BHR) was evaluated by airway 
responsiveness to inhaled histamine phosphate with the method described earlier141. 
Aerosols were generated through an automatic inhalation-synchronised jet nebulizer 
(Spira Elektro 2) equipped to provide an adjustable aerosol delivery time. Three 
concentration of histamine diphosphate were used (1, 8, 64 mg/ml). At each 
concentration 2, 4 and 8 breath were taken with FEV1 determined 3 minutes after each 
dose. The dose of histamine causing a reduction in FEV1 of ≥20% (PD20FEV1) was 
calculated by linear interpolation on the individual log-dose response curve. Airway 
hyperresponsiveness was defined when the cumulative dose of histamine inducing a 
reduction in FEV1 was ≤880µg (PD20≤880µg).  
 
3.2.8 Exercise test and BMI  
A submaximal exercise test on an ergometer cycle (Ergomed 824E, Monark, Sweden) 
was performed and evaluated as according to Åstrand and Ryhmning142-144. Since the 
exercise test was primary performed to estimate working capacity and not presence of 
exercise induced asthma each subject inhaled a β2-agonist and warmed up for 10 
minutes prior to the test. Heart rate was measured with a Polar sport tester (PE-3000, 
Polar Electro OY, Kempele, Finland). The initial workload was set to 0.5 or 1.0 kP on 
the basis of weight, gender and exercise habits and a constant pedal speed of 50 rpm 
was maintained throughout the test. Heart-rate was recorded every minute until steady 
state was reached. Lung function was measured prior to the test and after 1, 5 and 15 
minutes with a Vitalograph spirometer. 
Body-mass-index was calculated as weight in kg/(height in meter)2.  
 
 
 
3.3 METHODS PAPER III AND IV 
3.3.1 Cells 
Peripheral blood lymphocytes were purified from healthy donors using Lymphoprep 
density gradient separation and depleted of phagocytic cells by treatment with carboxyl 
iron and magnetic removal. When indicated, further enrichment of T cells was 
accomplished by depletion of CD56-, CD19- and CD14-positive cells using magnetic 
beads coated with the corresponding antibodies. 
The birch-specific (bet v) CD4-positive T-cell clone AF24 was obtained from XX. This 
T cell clone was stimulated with anti-CD3 or specific antigen.  In these latter 
experiments with antigens autologous B-cell were used as antigen presenting cells 
subsequently removed by CD19 coated beads. AF24 was cultured in presence of 10 
ng/ml IL-2 and, if not mentioned otherwise, in serum-free AIM-V medium (Gico Ltd., 
Paisly, UK). 
 
 
3.3.2 Cell proliferation  
Cell proliferation was determined as previously described 145.  
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3.3.3 Cell motility 
Collagen type 1 was diluted in serum-free RPMI 1640 and H2O (8/1/1), applied in 
plastic Petri-dishes 1ml/dish (30 mm; BD Biosciences) and allowed to polymerize at 
room temperature. A total of 1.0x106 cells in AIM-V medium was added to each well 
and allowed to migrate for different times. Cytochalasin B, 10µg/ml prevented 
migration into the collagen showing that it is an active cellular process. The cells were 
fixed in 2.5 % glutaraldehyde or for immunocytochemistry in 2% paraformaldehyde 
and washed twice with PBS. Cell morphology and cell migration were evaluated in 
nine fixed positions in each well and at 50 μm intervals throughout the gel by the use of 
an inverted microscope (Nikon Eclipse TE300) and a digital depth meter (Heidenheim 
ND221). The results are given as mean number of infiltrating cells/field (x 20 
objective) per infiltration depth (50 μm for the first two layers immediately beneath the 
gel surface and 100μm for other layers further down), as total number of infiltrating 
cells throughout the gel (x 20 objective) or as maximal infiltration depth. The 
infiltrating cells were identified in situ in the collagen gels using immunocytochemistry 
after fixation in paraformaldehyde. The transwell assay was performed using 48-well 
Boyden chambers. The lower wells were filled with RPMI containing 1 mg/ml BSA 
whereupon 8-µm nucleopore filters were placed in the chambers. The upper chamber 
was filled with 50 µl of 2x106cells/ml in AIMV. Following incubation for 1 hour the 
number of cells in the lower chamber was counted in triplicate.    
 
 
3.3.4 Cell adhesion 
To study cell adhesion, plastic Petri dishes (90 mm. Heger A/S, Norway) were coated 
with ICAM-1 (2 μg/ml), fibronectin (10 μg/ml) or poly-L-lysine (10 μg/ml) and 
extensively washed before use. The cells (10,000/position) in AIM-V medium were 
incubated on the substrates in a humidified CO2 incubator at 37C for 15 or 30 min. 
Cells were fixed in 2.4 % cold glutaraldehyde (GTA) for 10 min, unbound cells were 
removed by gentle aspiration or for identification using immunocytochemistry after 
fixation in 2% paraformaldehyde. The number of adherent cells per microscopic field 
(20 x objective) was counted. Cell adhesion was evaluated in nine fixed positions. 
Human plasma fibronectin and rat tendon collagen type I were purified and prepared as 
described elsewhere 146, 147 
 
 
3.3.5 Immunocytochemistry 
The expression of different antigens was determined by quantitative 
immunocytochemistry of cells fixed in 2% paraformaldehyde at 4° for 20 minutes 
attached to glass slides. Antigen expression was detected with mAbs and a complex of 
biotinylated peroxidise and avidin (Vector laboratories, Burlingame, Ca). For detection 
of intracellular antigens cells were fixed in 2% paraformaldehyde followed by washing 
in buffer containing 0.1% saponin. Staining intensity was quantified using a Nikon 
Eclipse E1000M microscope and the image processing and analysis program ImageJ. 
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3.3.6 Thrombospondin mRNA expression 
Messenger RNA was extracted as previously described (ref) and the RNA/protein ratio 
was estimated. Following PCR amplification of TSP-1 primers the product was mixed 
with loading buffer and separated on a 1.5% agarose gel containing 0,5 µg/ml ethidium 
bromide. 
 
3.3.7 Small interfering RNA-mediated gene silencing 
The expression of TSP-1 and LRP1 was suppressed using the human T-cell 
Nucleofector kit (Lonza, Köln, Germany) together with a Nucleafector device (Amaxa 
biosystems, Köln, Germany) as described by Bidere and co-workers (ref). T-cells 
(5x106) were resuspended in 100 µl nucleofector solution and transfected with 500 nM 
final concentration of small interfering RNA (siRNA) using protocol U14. The TSP-1 
and LRP1 siRNA (sense and antisens are described in table xx). The resulting degree of 
gene silencing and the effect on motility were determined 40 hr after introducing 
siRNAs. 
 
3.3.8 Biotinylation and immunoprecipitation 
Biotinylation of cell surface proteins on intact lymphucytes was performed with D-
biotinyl-e-aminocoproic acid-N-hydroxysuccinimide ester (biotin-7-NHS) as described 
by the manufactor (Roche Molecular Biochemical, Stockholm, Sweden).  Adherent 
cells were biotinylated and released by a scraper and subsequently lysed in lysis buffer. 
Immunoprecititation was essentially carried out with the specific antibodies coupled to 
protein G agarose beads to capture the protein of interest as described by the 
manufacturers (Roche). Proteins were separated from the beads and antibodies 
followed by separation by SDS-PAGE. The proteins were transferred to a  
nitrocellulose Hybond ECL membrane (Amersham, Little Chalfont, UK) and detected 
using the BMC chemiluminescence blotting kit (Roche) 
 
3.3.9 Western Blotting 
Proteins were extracted and dissolved in lysis buffer, separated by SDS-PAGE and 
electrophoretically transferred to a nitrocellulose membrane. After blocking overnight 
the filters were incubated with antibodies. Bound antigens were visualized by 
chemiluminescence using ECL Western blotting reagents and Hyperfilm TM 
(Amersham). 
 
3.4 METHODS PAPER V 
Study population 
Asthmatic patients (n=19) aged 18-26 yrs with allergic asthma were recruited from the 
asthma/allergic clinic at Huddinge University Hospital. All subjects fulfilled the 
American Thoracic Society criteria for asthma and had a skin prick test verified 
reaction (≥3mm) against birch pollen together with typical symptoms when exposed.  
Assessment of atopic diseases was carried out by a questionnaire regarding symptoms 
of asthma, rhinoconjunctivitis and atopic dermatitis.  Peripheral blood was drawn by 
standard procedure. Blood samples were also collected from 14 healthy controls and 7 
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patients having chronic plaque psoriasis recruited from the department of dermatology 
at the same hospital.  
 
Cell preparation, analysis of motility and quantitative immunocytochemistry  was 
performed as described in methods paper III and IV. 
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4 RESULTS AND DISCUSSION 
 
 PAPER I,  
4.1 ASTHMA MORTALITY  
 
4.1.1 – incidence and accuracy of death certificate  
During the 10-year period, 1994-2003, 75 deaths suspected to be due to asthma in 
individuals in the age-group 1-35 year old were reported and analyzed.  In 37 of these 
cases deaths due to asthma were confirmed by the Task Force. As shown in figure 2 the 
incidence of death due to asthma in this age-group decreased from 1.54 per million 
1994 to 0.53 per million in 2003. These results are in accordance with reports from 
several “western“ countries indicating a break in the trend of increasing mortality due 
to asthma in this age group35, 36. This decline is thought to be due to improvement in 
management of asthma, especially the introduction of inhaled corticosteroids and 
improved guidelines for treatment of asthma35, 36.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  The incidence of deaths due to asthma among 1-34 years old in Sweden 
from 1994 to 2003 as determined by the Task Force 
 
 
When analyzing studies of mortality from asthma it is important to know how 
accurately death certificates identify asthma deaths. Death certificate may report a 
disease as being either the underlying or a contributory cause of death which may have 
consequences as official statistics reflecting primarily the reported underlying cause34.  
In 46 cases asthma was recorded as the primary cause of death in the death certificate 
of which the expert panel disagreed about 14, indicating an over-estimation of 30%, 
Figure 2. Of the 37 deaths classified by the expert panel as being due to asthma this 
diagnose was not regarded as the primary cause of death in five cases indicating under-
estimation  
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Figure 3. Comparison of the cause of death according to the death certificate* and 
as evaluated by the Task Force**  
 
 
(false-negative rate) of 14%. Similar figures in underestimating death from asthma are 
reported from Great Britain (18%) and Canada (16%)34, 148, 149 In contrast, a Finnish 
study revealed a total (false positive and negative) misclassification of only 7% 150. 
Possible explanations to these divergent figures are circumstances such as methods 
used to estimate the validity of death certificates, investigated age span and criteria for 
defining “true asthma death”.  In our study autopsy was performed in 76% of cases but 
the usefulness of post mortem findings has been questioned in that microscopic as well 
as macroscopic findings may be uncharacteristic148, 151, 152. 
Except for two cases, all death reported directly to the Task Force by the medical 
profession were also documented in the death certificates indicating that most cases of 
suspected death due to asthma were analyzed by the expert panel. In spite of this our 
result, identifying 37 cases of death due to asthma, is probably an underestimation as 
the expert panel concluded that the information available was insufficient for confident 
determination of the cause of death in 12 cases.  
 
4.1.1 Risk-factors for asthma mortality  
Allergy to food and pet dander was the most prominent risk-factor associated with 
death by asthma in 19 subjects of whom only two belonged to the group of 30-34 years 
old adults, figure 4. An allergic reaction to food, especially allergy to soy and peanuts, 
was the major cause of death in the 1-19 years old individuals which is in line with 
previous reports31, 153, 154.  It is notable that a majority in this group was considered to 
have mild or moderate asthma which, to some extent, may be explained in that half of 
the subjects in this age group were on inhaled corticosteroids, figure 4. However, 
unexpected death in children with mild disease has been previously reported before 
inhaled corticosteroids was a general accepted regime in treating children with 
asthma31, 155. Our results are in accordance  
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Figure 4. Distribution of deaths due to asthma according to age, allergy and 
severity. 
 
 
with previous reports that almost all death caused by food anaphylaxis are due to 
anoxaemia caused by asthma31, 153, 154. The need of distinguishing anaphylaxis from 
acute severe asthma has been discussed as a predominance of respiratory symptoms in 
a patient having an anaphylactic reaction may be misdiagnosed as solely acute asphyxic 
asthma and subsequently result in undertreatment of the acute attack155. Our study 
revealed that in eight subjects, with a known allergy to pet dander, death was associated 
with exposure to this specific allergen which is a risk-factor previously seldom 
reported. In the majority of deaths caused by an allergic reaction the deceased were 
aware of their allergy but did neither avoid the specific item nor did they bring with 
them an auto-injector with adrenalin.   
Similar to what has been reported in several previous studies33 a great part, 17 out of 34 
patients for whom this could be assessed, had deteriorated in their asthma several hours 
or even days prior to their final attack. With only a few exceptions this group with 
increasing symptoms had delayed in seeking medical help.   
Under-treatment (n=23) was most evident in the groups of 20-29 and 30-34 years old.  
In 16 subjects under-treatment was due to the patients being non-adherent, in another 
six cases due to medical profession underestimating the severity and both for one 
individual. A possible link between asthma mortality and the use of long-acting β2-
agonists has been discussed; however in our material we found no such association156, 
157.  
 
 
Only two of 37 subjects who died due to asthma had not been previously diagnosed as 
asthmatic which is in line with a similar study from Denmark suggesting that a major 
part are known by the health care system prior to their final asthma attack33. Reliable 
lung function tests were available in a minority of cases in our material. However the 
value of such measurements in predicting asthma death is not established158. Becker et 
al could not show, in a newly presented study in adults, any correlation between BHR 
or FEV1 and mortality in asthmatics158.  
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Figure 5. Distribution of deaths due to asthma according to age and sex. 
 
As a majority of those who died due to allergic reaction had mild or moderately severe 
asthma, unawareness of the serious consequences of ignoring their disease could be a 
possible explanation. A relationship between poor perceptual accuracy of asthma 
symptoms and higher asthma morbidity and mortality has been shown159-161. The ability 
by the profession to improve the patient’s perceptual accuracy may ameliorate the 
quality of self-management plans160. In this context, an exercise test with dyspnoea 
scores has been suggested as a method to identify patients with a decreased perception 
of dyspnoea162. Altogether there are several circumstances indicating, in addition to 
optimal pharmacological treatment, a potential role of adequate patient/family 
education and individual management-plans in preventing mortality due to asthma33, 34, 
36.  
 
In contrast to previous studies33 no seasonal variation in the frequency of mortality due 
to asthma was detected in our study, irrespectively of the presences or absence of 
pollen allergy. The limited numbers of subject may explain this diversity. 
  
 
Drug and/alcohol abuse (n=8) and especially psychosocial problems (n=19) contributed 
to the death in the 30-34 year old adults pointing to the importance of identifying this 
group. The need and benefit of intervention in this subgroup of asthma patients is 
emphasized by reports that special clinics for such patients is shown to reduce asthma 
mortality163-165. Intravenous intake of narcotic drugs immediately before the fatal attack 
was found in 6 subjects.  Unexpectedly, five of these deaths were associated with 
amphetamine which, in contrast to deaths related to inhalation of heroin, has seldom 
been reported166.    
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4.2 PAPER II 
ADOLESCENTS WITH ASTHMA 
4.2.1 Risk-factors for asthma deterioration during transition 
from pediatric to adult healthcare 
As mentioned in the method section, factors analyzed as prognostic parameter were 
gender, poor adherence, exposure to tobacco smoke, pets at home, BMI, regular 
exercise, positive prick-test, treatment with inhaled corticosteroid or transfer to primary 
care. Neither lung function, working capacity nor BMI was affected by any of these 
parameters.  
Poor adherence to treatment was the only parameter with a negative impact on BHR at 
the five-year follow-up (OR 4.38) while regular physical activity had a positive impact 
on the same parameter at this time point (OR 0.34). A positive skin-prick test to furry 
animals and female gender had a negative impact on BHR at the time of entry into the 
study, Table 3.  These results are further presented and discussed below. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. The odds ratio (OR) obtained from logistic regression analysis of 
PD20FEV1 histamine < 880 μg. Statistically significant values are indicated in 
bold. The parameter values at the time of entry into the study were used as the 
independent variables, 
 
 
4.2.2 Atopy 
At entrance of the study, skin prick test revealed that among adolescents with asthma 
89% were sensitized towards at least one of tested allergens without any major changes 
during the course of the study. These figures had a clinical relevance with an 
association between symptoms and sensitization in 76.4% of those demonstrating a 
positive reaction to perennial allergens and in 82.5% in the case of pollen allergens.  At 
entrance of the study 28% demonstrated a positive skin-prick test to peanuts in some 
cases probably due to cross-reactivity to birch167. The high frequency of sensitization to 
pollen and furry animal among ours patients is in agreement with previous studies of 
similar groups of young people with asthma and does not reflecting incidence in the 
general population25, 26, 168. However, sensitization in the late adolescent period has 
been proposed to mediate a negative impact on the outcome of asthma in later 
adulthood4, 26. 
Table 2:  Odds ratios (OD) and 95% confidence intervals (95% CI) of logistic regression  analyses on PD20 ≤ 880 μg histamine. 
OR (95% CI),  P Value 
 
 At entrance  2-year follow up 5-year follow up All three obs pooled 
Pos skin prick test 2.39(0.28-20.66) p=0.43 10,9(1.30-91.70) p=0.028 10.07(0,95-106.9) p=0,06 5.10(1.19–21.70)   p=0,03 
”        ”      ”        ”     furred animal 4.88(1.62-14.65) p<0,01 2.86(0.88-9.28) p=0.08 0,32(0.07-1.46) p=0,14 1.76(0.83-3.74) p=0,14 
Pets at home* 1.57(0.58-4.23) p=0.37 2.00(0.69-5.7) p=0.20 0.99(0.33-2.84)p=1,00 1.14(0.71-2.78) P=0,32 
Inhaled steroids* 2.39(0.87-6.59) p=0.09 1.05(0.36-3.04)p=0.90 2.08(0.60-7.12) p=0,25 1.70(0.88-3.30) p=0,12 
Female sex 3.16(1.15-8.68) p=0,03 3.90(1.42-10.72) p=0.008 1.84(0.72-4.66) p=0,20 2.46(1.35-4.50) P<0,01 
Randomization prim care 0.58(0.15-2.17) p=0.42 0.98(0.27-3.45) p=0.97 0.36(0.10-1.32) P=0,12 0.61(0.26-1.44) p=0,26 
Poor adherence† 4.00(0.82-19.33) p=0.09 8.33(1.69-43.09) p=0.01 4.38(1.17-16.3) p=0,03 4.22(1.36-13.14) p=0,01 
Regular physical activity*  0.5(0.19-1.36) p=0.17 1.31(0.47-3.66) p=0.61 0.34(0.12-1,00)p=0,05 0.63(0.34-1.19)p=0,16 
BMI > 25* 0.32(0.08-1.28) p=0.11 2.03(0.53-7.77) p=0.30 0.76(0.22-2.57) p=0,66 0,90(0.41-1.97) p=0,78 
     
*at entrance. †poor adherence to asthma treatment 
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4.2.3 Lung function and bronchial challenge 
At entrance of our study 11% presented with a FEV1 < 80% of predicted of whom the 
majority improved while FEV1 deteriorated in 4 out of 104 subjects. No correlation 
was found between FEV1 or any tested risk-factors. As the majority of patients with 
FEV1 < 80% improved our result does not support previous reports suggesting a poor 
outcome in this subgroup of asthmatics25, 30, 169. Furthermore these results  indicate that 
lung function  is an insensitive indicator of asthma severity in the adolescent period an 
assumption in line with studies on younger teenagers170. However, we did not perform 
any bronchodilator reversibility test which might improve the benefit of lung function 
test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Normal and pathological results in PD20 histamine at entrance and 
follow up.  Pathological result: < 880 µg.  
 
Bronchial challenge with histamine showed that 71% had a bronchial hyperreactivity 
(PD20≤880 µg) at entrance, Figure 6.  Although the proportion of patients with BHR 
decreased during the study a considerable number deteriorated during the same period, 
Figure 7. This fluctuation in BHR may indicate that this subgroup still has “latent” 
asthma with an associated elevated risk for relapse as has been discussed previously24, 
26, 27.  
Although BHR, PEF variability and bronchodilator reversibility are important 
characteristics of asthma these markers cannot be used interchangeably, especially not 
in epidemiological studies as stressed by Ulrik et al171. This group quoted that BHR and 
PEF variability were significantly associated with FEV1 whereas bronchodilator 
reversibility was associated with FEV1/FVC ratio and subsequently they advocated 
bronchial challenge tests.  
 
 
 
 
PD20, histamine challenge 
     At entrance                             2 year follow up                    5 year follow up 
 
 
 
 
 
 
 
 
 
 
Fig 3.  
Figure demonstrating normal and pathological results in PD20 histamine at entrance and at 
follow up after 2 and 5 years. Pathological result: ≤ 880 ug histamine. 
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Figure 7. Bronchial responsiveness to histamine at the time of entry and in 
connection with the two- and five-year follow-ups. PD20FEV1 = the dose of 
histamine that caused a 20% reduction in FEV1 
 
 
4.2.4 Exercise test and physical activity 
Working capacity and BMI was evaluated in 123 subjects at entrance and repeated by 
91 of those in connection with the five-year follow-up. Although maximal exercise 
testing is considered the gold standard for assessing maximal aerobic capacity, the role 
of such testing is often limited in people whose performance is impaired by bronchial 
obstruction or fatigue rather than exertion143. Furthermore when a maximal exercise test 
is performed without achieving testing criteria such as age-predicted heart rate (e.g. due 
to muscular fatigue) the results are usually difficult to interpret172. As a consequence we 
used a submaximal exercise test (“Åstrand and Ryhmning (A-R) Cycle ergometer 
Test”) as described in “Methods” 142-144.  This test is based on the linear relationship 
between heart rate and oxygen consumption and has a high correlation with maximum 
oxygen consumtion173-176.       
 As shown in Figure 8 working capacity decreased significantly during the study period 
both if measured as total oxygen uptake or oxygen uptake in relation to weight the 
latter could be of importance as the BMI increased during the same period (se below). 
No significant correlation between the performed oxygen uptake and any of tested risk-
factors examined was observed. Participants in regular physical declined during the 
same period which we consider as the most likely explanation for the decreased 
working capacity. The exercise test was performed to estimate working capacity, and 
not to confirm exercise induced asthma, subjects were premedicated with a β2-agonist, 
presence of exercise asthma could not be excluded. However, only two subjects 
performed with a decrease in FEV1 of  >15% during the test.  
Physical activity levels are known to be falling among teenagers and young adults in 
most industrialised nations177-181 although the number of studies addressing a possible 
association with asthma in this age group is limited. However, our result indicates that, 
properly treated, presence of asthma would not prevent patients from participating in 
physical activities. Furthermore, when entering our study the majority (55.4%) 
exhibited high or very high working capacity which is inconsistent with their asthma 
being a limiting factor.  
 
 
 
 
Fig 1: Bronchial responsiveness to histamine at entrance and at 2 and 5 year follow up. PD20 denotes 
the dos of histamine causing a 20 percent decrease in FEV1. 
0
5
10
15
20
25
30
35
40
45
0-55 56-110 111-220 221-440 441-880 >881
Pe
rc
en
t o
f o
bs
er
va
tio
ns
PD20 Histamine
At entrance
2 year follow up
5 year follow up
 34 
This conclusion is in coherence with previous studies investigating children and adults 
with asthma67, 182, 183. In spite of this a majority of young people with asthma is reported 
to believe that their physical activity is reduced as a result of their disease184. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Assessment of working capacity (oxygen uptake) at the time of entryand 
the five-year follow-up. The data were categorized according to Åstrand. 
 
A possible explanation for these contradictory observations could be a vicious cycle of 
decreased physical activity leading to deterioration of fitness during the transition from 
being a teenager to becoming a young adult. This decline could also easily be 
misinterpreted as exercised asthma by the patient as well as by health care providers. 
However, our finding that regular exercise was associated with less pronounced BHR at 
the five year follow up  (p=0.004) may be an indicator that suffering from asthma 
exerts a negative effect on both the motivation for and possibility of performing 
physical activity, as discussed by Aaron et al185. An alternative explanation could be 
that regular exercise actually ameliorates BHR a matter that has been widely 
discussed180, 182. Of possible importance in this context is a study indicating that among 
young women regular physical activity increases heath-related quality of life186. 
Participating in sport activities has a documented effect on physical fitness and quality 
of life in children and adolescents187. Newly diagnosed adolescents with asthma have 
been shown to be less fit with lower physical activities as compared with healthy 
controls but improving after anti-inflammatory asthma treatment188-190.   
 
 
4.2.5 BMI 
When investigating influence of BMI we found no associations with any of the tested 
dependent variables, although the mean value for BMI increased from 22.4 to 23.8 
(SD3.8) during the study period. The numbers of patients with BMI>25 increased from 
24 (19%) to 32 (35%) at the same period, possibly the result of a sedentary life style as 
discussed earlier. Association between asthma and overweight is a matter of 
discussion191-193. However, in our study the increase of BMI did not correlate with 
results from histamine bronchial challenge.  
 
to pollen and furry animals observed here is in agreement
with previous studies on similar groups of young people with
asthma.5,9,18
In the present investigation, 9 of the 16 subjects with an
FEV1 �80% predicted improved to a value >80% within the
first two y ars following transfer to adult care, with only
minor further changes occurring during the subsequent
three-year period. Of even greater importance is our
finding that the FEV1 values of only four of 104 subjects
deteriorated from nor al to FEV1 �80% predicted during
this same period, suggesting that lung function is an
insensitive indicator of the severity of asthma during the
adolescent period. In c ntrast, subjects cl ssified s severe
asthmatics (i.e., with FEV1� 80% predicted) have been
shown to run an 80% risk of being moderately or severely
asthmatic 9 years later.7
One of the main characteristics of asthma is an
enhanced responsiveness to inhaled direct stimuli such as
histamine which has been recommended as an objective
marker of asthma-related airway lability n adoles ents and
young adults.19 In addition to this impaired sensitivity of
FEV1, another possible explanation for the present
discrepancy involving improvement in FEV1 in combination
with persistent BHR may be that BHR persists long after
asthma has been outgrown.5,20 Furthermore, the variation
in BHR over time documented here has received little
attention in patients of this age. As discussed by Vonk and
co-workers20 these results may indicate that this group of
patients still as ‘‘latent’’ asthma, with an associated
elevated risk for relapse. Here, the factors which exerted
a negative impact on bronchial responsiveness at the time
of the five-year follow-up were ‘‘poor adherence’’ and
atopy, whereas regular exercise was associated with
a positive impact on PD20. In addition, we observed that, as
reported previously, regular treatment with ICS had
negative influence on logPD20, which probably reflects the
influence of the severity of the asthma, since such use
indicates more severe disease5 and, moreover, use of ICS
was not a risk factor for BHR.
At the time of their entry into the study, female subjects
demonstrated a higher frequency of BHR than did the men,
although, in contrast to previous reports,5,21 this difference
could no longer be detected in connection with the five-
year follow-up. This phenomenon may be related to the
parallel finding that sensitization to furry animals also
ceased to be a risk factor for BHR after five years of follow-
up. Since a large percentage of the young women exhibited
a positive skin prick test to all three fender allergens, the
improvement in their BHR could be due to reduced expo-
sure to furry animals after leaving school22 and, possibly,
a home with a pet.
The patients classified as adhering poorly to the treat-
ment recommended for their asthma had a significantly
lower logPD20 and an increased risk for BHR in comparison
to those with better compliance. However, these former
patients exhibited no further deterioration with time sug-
gesting that the increased frequency of BHR in this group
was due to long-term undertreatment with no positive
change in attitude. The number of active smokers among
our population was small and difficult to determine accu-
ra ely. However, exposure to tobacco smoke from other
sources exerted no impact on either lung function or PD20.
An association between asthma and obesity has been
discussed in several studies that included adoles-
cents.2,7,23,24 In the present investigation, the mean BMI
values for our subjects increased significantly during the
five-year study period without any apparent deleterious
impact on lung function or any influence on bronchial
reactivity to histamine, indicating a lack of any physiolog-
ical effects of overweight per se on the conducting airways
in this subgroup of our asthmatic subjects. However, this
lack of correlation should be interpreted cautiously, since
only three of our participants had a BMI >30.
We chose here to employ a submaximal test to assess
physical fitness, since the relationship between heart rate
and oxygen consumption or workload is essentially
linear.16,17 At the time of entry into the study, relatively few
of our subjects were physically unfit and 55.4% exhibited
a high or very high oxygen uptake. However, by the time of
the five-year follow-up working capacity was reduced
(Fig. 3) and not as a consequence of the increase in BMI,
s nce oxygen uptake expressed as ml/kg was lower as well.
One possible explanation for this reduction in working
capacity could be the parallel decline in the number of
subjects who exercised regularly. In the late teenage years,
adolescents are generally not offered organized participa-
tion in sporting activities and initiative for exercise must be
taken on an individual basis.25 In this context, our finding
that regular exercise was associated with less pronounced
BHR may be an important indicator that suffering from
asthma exerts a negative influence on both the motivation
for and possibility of performing physical activity.25 It is also
possible that regular exercise actually ameliorates BHR with
subsequently beneficial effect on asthma as suggested by
Rasmussen et al.26 It is well known that asthmatic adoles-
cents often complain that their physical capacity is
impaired, suggesting exercise induced asthma (EIA),27
although our results indicate that impaired working capacity
(oxygen uptake) may offer a more plausible explanation.
Figure 3 Assessment of working capacity (oxygen uptake) at
the time of entry and the five-year follow-up. The data were
categorized according to A˚strand.16
Adolescents with asthma 185
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4.2.6 Adherence to treatment and consequences of transition 
to adult health care     
In our study, 24% of those who participated in the entire five –year study (n=104) were 
characterized as demonstrating “poor adherence” to asthma treatment in despite of 
several efforts to overcome issues such as forgetfulness and ignorance. This subgroup 
of patients had a significantly lower logPD20 and an increased risk for BHR in 
comparison to those with better compliance emphasizing the need of some sort of 
intervention. As the group of those with poor adherence exhibited no further 
deterioration during the study this suggests that the increased BHR in this subgroup 
was due to long-term undertreatment. In the light of increased denial of their asthma 
among males, mentioned above, we could not show any relation to gender when 
analyzing those with poor adherence. A typical manifestation of poor adherence is non-
attendance to scheduled appointments, which is reported to be higher than average in 
asthma clinics10, 194-196. Telephone reminders have been shown to improve 
attendance196, 197and may be replaced by new media such as SMS-messages198.     
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4.3 PAPER III  
A cytokine-controlled mechanism for integrated regulation of lymphocyte 
motility, adhesion and activation 
 
A major function of T cells is to scan APC´s for antigenic peptides in the context of 
self-MHC throughout the body whereupon recognition of cognate antigens arrests 
motility and initiates specific proliferative responses49, 199. To carry out this function T 
cells continuously recirculate between blood and tissues through adhesion to 
endothelial cells accompanied by diapedesis hereafter the cells migrate in lymphoid and 
non-lymphoid tissues200, 201. In contrast, induction of antigen-specific tolerance prevents 
the arrest of motility.  Therefore, the coordination of T cell motility, adhesive 
interactions and proliferation most likely plays a pivotal role for regulation of immune 
responses and tolerance. However, very little is known about this coordination. Another 
important issue, which remains poorly understood, concerns how the vital T cell 
functions motility, adhesion and proliferation are influenced by external stimuli via 
cytokine receptors.   
 
The responsiveness of cells to external stimuli, such as integrin ligands and cytokines, 
is generally assumed to reflect signalling from a preformed landscape of surface 
receptors to intracellular networks. However, this concept does not explain how 
different stimuli are integrated by the cell. We examined the possibility that 
communication between cell surface receptors may be part of a dynamic cell-intrinsic 
regulation of T cell function with special reference to motility and adhesion.    
 
To study the influence of TSP-1 and LRP1 on cell-shape, adhesion and motility we 
used SiRNA-mediated gene silencing of these proteins in blood T cells. Transfection 
with LRP1 SiRNA induced a switch in cell-shape from a polarized motile to an apolar 
rounded morphology and inhibited migration into a 3D collagen gel accompanied by 
increased adhesion to ICAM-1. T cells transfected with TSP-1 SiRNA showed a a 
polarized and elongated motile cell shape together with impaired adhesion to ICAM. 
Silencing of TSP-1 had an inhibitory effect on T cell migration although not as strong 
as LRP1 SiRNA (Figure 1, paper III). These findings indicate that LRP1counteract 
adhesion and induces motility. In addition, motility obviously requires interactions with 
TSP-1  
 
AG 490, an inhibitor of the JAK-STAT signalling pathway, mediated reactions similar 
to knocking LRP1 i.e. increased adhesion and cell surface expression of  
TSP-1together with decreased motility (Figure 5, paper III). These results indicate that 
LRP1 promotes processing of TSP-1 via JAK-signalling with accompanying effects on 
adhesion and motility.  
 
To further explore a possible interaction between LRP1 and TSP-1 we used short 
peptides mimetic of binding sites in TSP-1; 4N1K, a peptide mimetic of the C-terminal 
CD47-binding site in TSP-1 and hep 1, a peptide mimetic of the N-terminal calreticulin 
binding site of TSP-1.    
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4N1K increased motility and cell surface expression of both LRP1 and TSP-1. The 
4N1K-induced effect on motility was abrogated by knockdown of LRP supporting that 
motility requires interaction between LRP1 and TSP-1 (Figure 4, paper III). 
Addition of pertussis-toxin, an inhibitor of the Gi protein complex, inhibited the 
expression of LRP1 but not TSP-1 indicating that the 4N1K/CD47 induced cell surface 
expression of LRP1 and TSP-1 was mediated through different pathways.  
 
Hep 1, increased cell surface expression of TSP-1 and inhibited motility. A similar 
increase of TSP-1 was also seen after silencing LRP1 (Figure 4, paper III). As LRP1 is 
a co-receptor for calreticulin these results suggest that TSP-1 disappeared from the cell 
surface through a process involving the calreticulin-LRP1 complex while 
simultaneously stimulating motility. This process seemed to be associated with 
degradation of TSP-1 dependent on calreticulin/LRP1 (Figure 5, paper III). 
 
Shear flow, is reported to stimulate T cell adhesion to ICAM-154. We could show a 
possible mechanism explaining this observation in that free-floating cells exhibited a 
marked up-regulation of the cell surface expression of TSP-1 (Figure 5, paper III). This 
is in agreement with the experiment using hep-1 showing that up-regulation of TSP-1 
induce T cell adhesion. 
 
IL-2, in contrast to anti-CD3, increased synthesis and expression of TSP-1 and 
stimulated motility. IL-4 had no effect on TSP-1 but increased expression of LRP1 
while simultaneously hampering motility.  
 
Originally, in order to exclude knocking experiments generating negative effects on the 
cells, anti-CD3-induced DNA synthesis was estimated. However knockdown of TSP as 
well as an anti-CD47 antibody increased anti-CD3-induced DNA synthesis (Figure 6, 
paper III).  These results points to an inverse relation between motility and proliferation 
which could be of importance in modulation immunological reactions in that activated 
T cell stop migrating and start to proliferate, a reaction stimulating inflammatory 
response. 
 
In conclusion the results presented in paper III demonstrate that LRP is necessarily for 
T cell motility and that the motogenic LRP/TSP-1mechanism antagonizes adhesion to 
ICAM-1 and fibronectin as well as TCR induced proliferative responses (Figure 9 in 
thesis). This cascade mediates regulatory effects of IL-2 and IL-4. In addition 
expression of TSP-1, with known ability to protect against inflammation, was increased 
by IL-2.  
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Figure 9. summarize the first part of this section and describe a cell surface 
cascade for integrated regulation of T cell motility, adhesion and TCR- and 
cytokine-induced responses. Motility is directed by cell surface-expressed LRP1 
and TSP-1. LRP1 expression at the cell surface promotes polarized cell shape and 
migration through JAK signalling while concomitantly inhibiting adhesion to 
ICAM-1 and fibronectin. ERK inhibits this motogenic effect. Cell surface 
expression of LRP1 is enhanced by interaction of the C-terminal domain of 
endogenous TSP-1 with CD47, whereupon interaction of the NH-2-terminal 
domain with LRP1 further enhances the motogenic effect of LRP1. IL-2 
stimulates synthesis and cell surface expression of TSP-1 and hence up-regulates 
the motogenic mechanism. IL-4 inhibits the motogenic mechanism. The motogenic 
mechanism inhibits TCR-induced T cell proliferation. TCR-induced proliferative 
responses and IL-4 inhibits the motogenic mechanism. “+” denotes stimulatory 
effect, “–“ denotes inhibitory effect.   
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4.4 PAPER IV 
The TCR Collaborates with CD28 to regulate T cell Motility and an Anti-
Inflammatory Response through Endogenous TSP-1 and LRP1 
 
Antigen challenge in vivo changes the motile behavior of T cells from a random walk 
to arrested migration, contact with and swarming in the proximity of APC cells 
inducing a proliferative response 59-61 . In contrast, antigen specific tolerance does not 
induce this arrest of migration and swarming 74. As previously discussed the balance 
between T cell motility and adhesion is of great importance to maintain protection from 
infections and tumors without generating autoimmunity59-61, 72, 74, 202, 203. However, in 
spite of its fundamental importance for immune regulation the mechanism responsible 
for this altered migration by antigen is poorly understood. 
 We examined the possibility that antigen stimulation influenced T cell motility 
through the mechanism for integrated regulation of T cell motility, adhesion and 
proliferation dependent on LRP1 and endogenous TSP-1 as described in Paper III. 
Using three model systems, an allogeneic MLC, a birch allergen specific human T-
cell clone (AF24) and blood T cell activated by antibodies to CD3 and CD28. 
Analysis of these model systems showed that an allogeneic MLC exhibited a 
powerful increase of synthesized TSP-1together with a simultaneous down-regulation 
of LRP1 synthesis and motility in contrast to T cells from the individual donors or 
MLC depleted of CD3 cells (Figure 1, paper IV).  In the model using the AF24 T cell 
clone we showed a reverse relationship between motility and adhesion on fibronectin 
(Figure 5, paper IV)  
Blocking the CD28 co-stimulating signal with abatacept virtually abolished surface 
expression of LRP1 and TSP-1 in MLC activated T cells (Figure 1, paper IV) and a 
remaining impaired motility was almost totally inhibited. To further examine the effects 
of co-stimulation we could show that anti-CD3 increased transport of TSP-1 out to the 
cell surface while CD28 increased cell surface expression of LRP1.  In contrast RT-
PCR revealed that anti-CD28 was permissive for synthesis of both LRP1 and TSP-1 
while anti-CD3 alone as well in co-ligation with anti-CD28 almost completely 
suppressed mRNA synthesis of LRP1 and TSP-1 (Figure 2, paper IV).  
 
The pronounced up-regulation of TSP-1 synthesis by antigen stimulation has several 
important functional implications as depicted in Figure 3 (paper IV) such as induce 
adhesion and macrophage activation, preventing angiogenesis and inflammation.  
 
In conclusion, as depicted in Figure 10 (in thesis), our results indicate that the TCR 
induced arrest of motility reflects down-regulation of LRP1 synthesis. The concomitant 
up-regulation of TSP-1 synthesis may provide a mechanism for enhancement of 
adhesion of T cells to APC´s stimulating proliferative responses. An additional 
possibility is that the TCR induced TSP-1 synthesis prevents autoimmune and allergic 
diseases. 
Furthermore, we reveal that, despite this arrest of motility, co-ligation with CD28 
maintains a basal motility level by enhancing transport of LRP1 to the cell surface. 
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Figure 10. TCR-induced co-stimulation-dependent regulation of T cell functions 
through TSP-1 and LRP1. Co-stimulation of the TCR and CD28 regulates T cell 
motility through differential effects on LRP1 and TSP-1 synthesis and cell surface 
expression thus eliciting a powerful TSP-1 response/synthesis while down-
regulating LRP1. Ligation of CD28 per se enhances cell surface expression of 
LRP1 and development of a polarized cell shape, whereas ligation of the TCR 
alone inhibits motility through inhibition of the expression of TSP-1 and LRP1. 
CD28 ligation thus counterbalances the inhibitory effect of TCR ligation alone on 
T cell motility. The up-regulation of the proadhesive, antiinflammatory and 
antiangiogenic protein TSP-1 probably serves to enhance the corresponding 
functions.  
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4.5 RESULTS PAPER V, 
Dysfunctional Regulation of T cell Motility in Patients with Allergy and 
Autoimmunity 
 
Many autoimmune diseases are characterized by tissue destruction mediated directly or 
indirectly by T cells and also involving both the humoral and innate immune system. T 
cells are thought to play an important role in orchestrating inflammation and infiltrate 
affected organs in both autoimmune and allergic diseases204, 205. 
 
T cells from patients with allergy and psoriasis are usually analyzed using cell surface 
markers defining different subsets, state of activation and proliferative capacity134, 205, 
206. Although T cell motility play an important role in the regulation of immune 
responses included tolerance and effector functions motility has been little studied in 
these patients. However, mice with specific loss of CCR4 in their Treg cells have been 
shown to develop severe pulmonary disease implicating an important role for adequate 
T cell migration207.    
In our study T cells from teenagers and young adults with allergic asthma showed a 
significant reduction of migration into a 3D collagen matrices compared with both 
healthy controls and subjects with psoriasis. Cells from patients with psoriasis also 
showed impaired migratory capacity compared with controls but to a lesser extent in 
comparison to those with allergy (Figure 1, paper V).  
 
According to our results presented in paper III and IV the impaired motility in patients 
could reflect decreased cell surface expression of TSP-1. Compared to controls, 
patients with allergy showed a lower cell surface expression of TSP-1 groups (Figure 3, 
paper V). Our results reflect an average of TSP-1 expression on T cells and not solely 
the allergen specific T cell subgroup possible explaining the moderate difference.   As 
the latter subgroup of T cell is small relation to the whole cell population our results 
could represent a constitutional characteristic of the individuals T cell population 
rendering the individual more prone to suffer from autoimmune diseases. However, 
such a constitutional defect seems unlikely since it likely would be associated with a 
range of other autoimmune disorders which is not the case.  
 
IL-2 was shown to up-regulate the impaired motility in patient to the same level as in 
controls indicating a reversible state further excluding a constitutional defect (Figure 2, 
paper V). 
However, in the presence of IL-2 control cells exhibited an even higher level of 
motility compared to cells from those with an allergic disease but without any 
significant differences when calculated as percent of increase in migratory capacity. 
Another possible explanation, as suggested by our previous findings, is that the reduced 
motility in patients with allergy and psoriasis reflects an ongoing antigen stimulation.  
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5 MAIN RESULTS AND CONCLUSIONS 
 
 A majority of teenagers and young adults with asthma are atopics and 
sensitized to allergens such as pets and pollen resulting in persistent exposure 
and subsequently high risk of having a chronic inflammation in their airways. 
 
 Allergic reaction in form of asthma is involved in a substantial numbers of 
deaths due to asthma. 
 
 Psychosocial factors such as denial and poor adherence to recommended 
treatment are associated with death due to asthma and increased bronchial 
hyperactivity indicating inflammatory activation in the airways. 
 
 LRP1 and TSP-1 and interaction between these proteins regulate T-cell 
motility and adhesion. 
 
 Interleukin-2 stimulates TSP-1 synthesis and motility and IL-2 and IL-4 
interregulate through LRP1 and TSP-1. 
 
 T cell activation induces arrest of T cell motility through down-regulation of 
LRP1 synthesis 
 
 T cell activation up-regulates the synthesis of TSP-1 which may enhance T cell 
adhesion to antigen-presenting cells and prevent inflammation. 
 
 CD28  regulates the  cell- surface expression of LRP1.  
 
 Patients with allergy and psoriasis showed impaired T cell motility and 
decreased TSP-1 expression compared to healthy controls. 
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6 FUTURE PERSPECTIVES 
 
Future perspectives 
Our results point out how important it is that transition from pediatric to adult health 
care be well prepared and planned long in advance to give teenagers  the opportunity to 
enter adult life without being hampered by their disease.  Health care must empower 
young people to help facilitate their own transition by becoming self-aware, fully 
engaged and expert on their disease.  
To achieve this and to prevent deterioration in their disease, and, in the worst-case 
scenario, death due to asthma, we need to improve patient education, including training 
in the perception of serious symptoms.  
The drastic deterioration in working capacity that we have observed during the 
transition period needs to be actively prevented. How such prevention should be 
optimally organized requires further studies in collaboration with experts in 
psychosociology and physiotherapists. 
For those with a more serious disease specialized ‘transition-clinics’ could be of 
importance in achieving optimal asthma management. These clinics have to be 
organized and maintained in close co-operation between pediatric and adult health 
services.  
Further studies are needed to identify those patients with risk factors associated with 
serious deterioration or death due to asthma.    
 
 
 
The demonstration in the present studies of an integrated mechanism for regulation of T 
cell adhesion, migration and TCR-induced proliferative responses may provide a 
background for development of therapeutic tools to promote tolerance and interfere 
with adverse inflammatory responses. 
 
Patients with asthma/allergy and psoriasis presented with decreased T cell motility and 
expression of TSP-1.The mechanisms behind these findings are unclear. As T cell has 
major role in autoimmune diseases and allergy these results may have of both 
diagnostic and therapeutic value. 
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Astma är en av de vanligaste sjukdomarna hos tonåringar samt unga vuxna. 
Prevalensen (förekomsten) för astma i dessa åldersgrupper rapporteras i flertalet 
undersökningar ligga mellan 6-10% varav flertalet insjuknat före sex års ålder. 
Prognosen vid astma anses bättre ju tidigare sjukdomen debuterar. En betydande del av 
barn och ungdomar med astma fortsätter att ha symtom även i vuxen ålder.    
Dödsfall på grund av astma hos barn, ungdomar samt unga vuxna är numer ovanliga. 
Under 80-talet noterades dock en oroande ökning i Sverige. I USA är astma den 6é 
vanligaste dödsorsaken bland barn i åldern 5-14 år. När astmasjukdomen debuterar före 
eller i tidiga tonår, anses förekomst av allergi spela en stor roll för den inflammation 
man ser vid astma.   
Vid allergisk astma orsakas inflammationen i luftvägarna av kroppens immunsvar mot 
allergener (allergiframkallande ämnen, t ex pollen). Denna reaktion medieras av ett 
flertal olika celltyper varav T cellen är en.  
T cellerna reglerar det adaptiva immunsvaret mot främmande antigen (antigen = 
substans som kroppens immunsystem reagerar mot, t ex bakterier) men upprätthåller 
normalt tolerans mot kroppens egna vävnader men även mot främmande ämnen som 
normalt inte är skadliga. Om denna tolerans försämras kan immunsystemet reagera mot 
sig själv varvid autoimmuna sjukdomstillstånd som psoriasis och reumatism kan 
uppträda. På samma sätt kan immunsystemet reagera mot normalt ofarliga ämnen som 
exempelvis björkpollen varvid en allergisk reaktion uppträder.  
Arbete I. Med denna studie ville vi undersöka förekomsten av dödsfall på grund av 
astma i åldersgruppen 1-34 år samt försöka finna riskfaktorer för att i denna 
åldersgrupp avlida på grund av astma. 
Under en 10-årsperiod gick vi igenom samtliga dödsbevis som angav astma eller 
likartad diagnos som direkt eller indirekt dödsorsak. För varje misstänkt dödsfall på 
grund av astma införskaffades sjukjournal, obduktionsresultat samt i förekommande 
fall polisrapport. Där så var möjligt genomfördes även intervju med närmast anhörig. 
En expertpanel bedömde om de enskilda dödsfallen var orsakade av astma samt om 
bakomliggande riskfaktorer förelåg.   
Under perioden1994-2003 kunde vi identifiera 37 dödsfall orsakade av astma. Den 
årliga incidensen minskade från 1,54 till 0,53 dödsfall per million individer i aktuella 
åldersgruppen. Som främsta riskfaktorer för död på grund av astma konstaterades 
förekomst av allergi och psykosocial problematik med dålig följsamhet till ordinerad 
behandling men även i några fall dålig handläggning från sjukvårdens sida. Ett 
anmärkningsvärt fynd var att 11 av de 37 dödsfallen sannolikt orsakades av en allergisk 
reaktion mot föda vilket var den vanligaste orsaken bland dem under 19 års ålder. En 
stor del av de ungdomar som ingick i denna grupp ansågs ha en lätt till måttligt svår 
astmasjukdom. Åtta dödfall skedde i anslutning till exponering för pälsdjur. Bland de 
som avled på grund av astma i åldersgruppen 19-34 år ålder var en psykosocial 
problematik vanlig. Vi kunde även konstatera att dödsbevis påtagligt ofta innehöll 
inkorrekta uppgifter om dödsorsak.    
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I arbete II undersöktes under en femårsperiod ungdomar med astma i samband med 
överföring från barnklinik till vuxenvård. Syftet med studien var att undersöka 
riskfaktorer under denna period som riskerar medföra försämring av patienternas 
astmasjukdom. 150 ungdomar rekryterades i samband avskrivning från Barnliniken 
Huddinge sjukhus (numer Astrid Lindgrens barnsjukhus, Huddinge). Av de med 
lindrig/måttlig astma randomiserades hälften till öppen vård medan samtliga övriga 
deltagare följdes upp på Lung- Allergikliniken Huddinge. Samtliga deltagare 
genomgick upprepade undersökningar innefattande ffa allergiutredning, lungfunktion, 
arbetsprov o bronkialprovokation. 
Som främsta resultat konstaterades att 89% av deltagarna hade ett allergiskt inslag, de 
behöll en god lungfunktion medan en stor andel uppvisade en kvarstående, men över 
tid, påtagligt varierande bronkiell hyperreaktivitet (BHR, överkänslighet i luftvägarna). 
Riskfaktor för en kvarstående BHR var dålig följsamhet till ordinerad 
behandling/uppföljning. Konditionen försämrades påtagligt under studietiden men utan 
att påverkas av undersökta riskfaktorer. Gruppen med lindrig/måttligt svår astma som 
randomiserades till öppen vård uppvisade likartade resultat jämfört med motsvarande 
grupp som följdes upp på specialistklinik. 
Arbete III. Som bland annat framgår av delarbete I och II står det allergiska inslaget för 
en betydande del av såväl sjuklighet som dödsorsak vid astma. Det är ett välkänt 
faktum att T cellerna är av stor betydelse för att såväl initiera som modulera den 
allergiska inflammationen.  I delarbete III var intentionen att studera grundläggande 
mekanismer som reglerar T cellernas migration (rörlighet), adhesion ( att fastna) och 
aktivering av antigen. Specifikt har vi undersökt hur de två proteinerna 
thrombospondin-1 (TSP-1) samt lipoprotein receptor-related protein 1  (LRP1) 
påverkar  T cellens motila (rörliga) egenskaper och hur dessa interagerar med 
extracellulärmatrix (bindväv) samt IL-2 och IL-4, signalämnen vilka anses ha stor 
betydelse i den allergiska inflammationen 
Vi visade här att TSP-1 och LRP1 reglerar T cellens motila och adhesiva egenskaper. 
Resultaten visade också att interleukin-2 ökade cellens produktion av TSP-1 och 
motilitet, medan IL-4 hämmade motilitet. Vi har även påvisat intracellulära signalvägar 
som används vid de reaktioner där TSP-1 och LRP1 påverkar T cellens motila 
beteenden.  
I arbete IV, som är en fortsättning på delarbete III, studeras  de mekanismer som ligger 
bakom hur T cellens motila egenskaper regleras av dess  specifika receptor (TCR). Vi 
beskriver här hur ligering (sammankoppling) av TCR med den co-stimulerande 
molekylen CD28 påverkar förekomsten av komponenter som reglerar T cellens motila 
samt adheranta egenskaper, framför allt TSP-1 och dess receptor LRP1. Denna 
reglering har även en vidare betydelse genom att TSP-1 har anti-inflammatoriska 
egenskaper. Våra resultat visar även att, genom antigenstimulering, aktiverade T celler 
leder till en stark ökning av T cellens produktion av TSP-1 samtidigt som produktionen 
av LRP1 och cellernas motilitet minskade. Om man i samma modell blockerade co-
stimuleringen försvann såväl TSP-1 som LRP1 från cellernas yta samtidigt som deras 
motila egenskaper upphörde helt. 
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Sammantaget talar våra resultat för att TCR (T cellens receptor för olika substanser, t 
ex pollen) och CD28 genom att påverka T cellens motila egenskaper samt stimulera 
produktionen av TSP-1 kan inducera ett antiinflammatoriskt svar på stimulering. 
Arbete V. I detta arbete undersöktes T celler från unga vuxna med verifierad allergi 
mot björkpollen samt från patienter med psoriasis. Specifikt studerades uttrycket av 
TSP-1 samt T cellernas migration in en gel av kollagen (liknar bindväv). T celler från 
patienter med allergi uppvisade signifikant lägre motilitet men ökat uttryck av TSP-1 
jämfört med friska individer.  T celler från patienter med psoriasis uppvisade en 
intermediär nedsättning av motilt beteende medan uttrycket av TSP var i nivå med 
allergipatienterna.   
Sammanfattningsvis framkommer från denna avhandling att dödligheten på grund av 
astma minskat under 10-årsperioden 1994-2003. En stor del av dödfallen orsakades på 
grund av exponering för en faktor som vederbörande var medveten om att han/hon var 
allergisk mot. En annan riskfaktor var en bakomliggande psykosocial problematik. 
Vidare konstateras att en överväldigande majoritet av tonåringar då de lämnar 
barnhälsovården har någon form av allergi. Majoriteten har en bronkiell 
hyperreaktivitet (BHR) som framför allt kvarstår hos dem som ej skötte sin 
astmabehandling medan den minskade hos dem som tränade fysiskt regelbundet. 
Studiedeltagarnas kondition minskade påtagligt under studietiden men utan samband 
med någon av de undersökta riskfaktorerna. Sammantaget visar dessa resultat på vikten 
av en planerad överföring av ungdomar från barn till vuxenvård, behovet av 
patientutbildning samt förmågan från sjukvården att identifiera riskpatienter. 
Det faktum att T celler från patienter med allergi och psoriasis hade en nedsatt motilitet 
medan IL-2, som förebygger och används vid behandling av dessa tillstånd, stimulerar 
motilitet kan tala för att den motilitetsstimulerande effekt som vi visat av TSP-1/LRP1 
kan ha betydelse för att monitorera samt behandla autoimmuna samt allergiska 
sjukdomar.  
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